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Objective: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to have
pleiotropic effects in addition to their lipid-lowering properties. Some studies have shown the beneficial effect
of preoperative statins on operative outcomes in coronary artery bypass grafting. However, the effect of preop-
erative statins in patients without coronary artery disease who undergo cardiac surgery remains poorly defined.
Methods: We performed a retrospective review of 1389 consecutive patients undergoing cardiac valve surgery
between January of 2002 and December of 2005. Patients undergoing concomitant coronary artery bypass sur-
gery and those with a history of myocardial infarction and coronary interventions were excluded. Of this cohort,
363 patients were receiving a statin preoperatively and 1026 patients were not. Propensity scores were constructed
with patients’ demographics, clinical data, and the year of procedure. Generalized estimating equations, including
the propensity score as a covariate, were used to investigate whether preoperative statin use is associated with
improved operative outcomes.
Results: The crude operative mortality rate was 0.8% and 2.3%, the incidence of stroke was 1.7% and 2.9%, and
the incidence of perioperative myocardial infarction was 2.2% and 2.4% in the statin and non-statin groups, re-
spectively. Generalized estimating equations showed that preoperative statin use is associated with lower mortal-
ity (odds ratio: 0.25, 95% confidential interval: 0.12–0.54). Preoperative statin use was not significantly
associated with an incidence of stroke (odds ratio: 0.48, 95% confidential interval: 0.19–1.22) or perioperative
myocardial infarction (odds ratio: 0.91, 95% confidential interval: 0.43–1.91) in this cohort.
Conclusion: Preoperative use of statins may improve operative outcomes in patients without coronary artery
disease who undergo cardiac surgery.3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors (statins) are potent cholesterol-lowering medications
used primarily for hypercholesterolemia. They have been
shown to have cholesterol-independent pleiotropic effects:
to improve endothelial function, stabilize atherosclerotic
plaques, decrease oxidative stress and inflammation, and
inhibit the thrombogenic response.1
Statins have been shown to reduce the incidence of coro-
nary events and stroke2 and are effective in the prevention of
major cardiac events in coronary artery disease (CAD).3-9 In
the field of cardiac surgery, some retrospective studies
have shown that preoperative statin use reduces mortality
and morbidity after coronary artery bypass grafting
(CABG).10-12 However, the effect of preoperative statins
in non-CABG cardiac surgery is unclear. Pleiotropic effects
of statins could attenuate the adverse effect of surgical inva-
siveness and the proinflammatory milieu that ensues after
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The aim of this study is to assess the association of preop-
erative statins with early operative outcomes of cardiac sur-
gery without CAD. We hypothesize that preoperative use of
statins reduces operative mortality, stroke, and perioperative
myocardial infarction (PMI) in patients without CAD who
undergo cardiac surgery.
MATERIALS AND METHODS
Study Design and Data Collection
We conducted a retrospective cohort study reviewing 1389 patients who
underwent cardiac valve surgery between January of 2002 and December of
2005. We included the most recent 4 years to minimize time-related
confounding factors.
All adult patients undergoing any cardiac valve surgery with CPB at
Brigham and Women’s Hospital during this period were included in this
study. We exclusively extracted clinical data on the patients undergoing
cardiac valve surgery within our database. Exclusion criteria included age
less than 18 years old, emergency salvage surgery, significant CAD on pre-
operative angiography, previous myocardial infarction, previous CABG,
previous or planned percutaneous coronary interventions, concomitant
CABG, and concomitant ventricular assist device implantation. We evalu-
ated coronary arteries with preoperative angiography for all patients except
those who were younger than 40 years of age and who had no apparent risk
factors for atherosclerotic disease.
Preoperative use of statins was defined as being prescribed any class of
statins at the time of admission. By this definition, we found 363 patients
taking statins before surgery and 1026 patients not taking statins. A total
of 197 patients (54.3%) were taking atorvastatin, 126 patients (34.7%)urgery c December 2008
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patients (2.2%) were taking fluvastatin, 7 patients (1.9%) were taking lov-
astatin, and 4 patients (1.1%) were taking rosuvastatin (Table 1). Routine
preoperative management included continuing preoperatively prescribed
statins until the day before surgery; no statins were newly prescribed before
surgery, and statins were restarted after surgery in all patients who were
taking statins before surgery.
Operative mortality was defined as a death within 30 days after sur-
gery or during the same hospitalization. Stroke was defined as a centra
neurologic deficit persisting postoperatively for more than 72 hours dur-
ing the hospitalization. PMI was defined as postoperative elevation of
creatinine kinase-MB isoenzyme of more than 100 U/L (20 times higher
than the upper normal limit in our laboratory) at any time during the
immediate postoperative period during the current hospitalization
Creatinine kinase-MB isoenzyme was routinely assessed in all cases
No patients had postoperative coronary angiography or intervention in
this cohort.
Aortic valve disease, mitral valve disease, and tricuspid valve disease
were considered present if surgical replacement or repair of each valve
was performed. Other cardiac disease was considered present if the opera-
tion included concomitant non-valve surgery, such as congenital heart sur-
gery, atrial fibrillation surgery, and thoracic aortic surgery. All other
variables were defined on the basis of the definitions provided by the
Society of Thoracic Surgery National Adult Cardiac Surgery Database
version 2.52.
All data were collected from the Brigham and Women’s Hospita
Cardiac Surgery Database and medical records. This study was approved
by the institutional review board (IRB Protocol 2004p000028) of Brigham
and Women’s Hospital.
Data Analysis
Patients’ demographic, clinical characteristics, and the year of procedure
were compared between the statin and non-statin groups. We used an
unpaired t test for continuous variables and a chi-square or Fisher’s exac
test for categoric variables. Continuous variables are expressed as mean
 standard deviation.
We used propensity scores for risk adjustment because the numbers of
outcome events were low and there were multiple confounding factors.13
We built a propensity score model for taking preoperative statins, including
all variables listed in Table 2 to adjust for those confounding factors. The
C-index of the propensity score model was 0.77. Furthermore, to assess
whether preoperative statin use is associated with the incidence of operative
mortality, stroke, and PMI, we used the propensity scores in regression
adjustment.14 We used generalized estimating equations to adjust for sur-
geon cluster effects.15 We included a propensity score and the CPB time
TABLE 1. Preoperative statins and doses
Statin and dose No. of patients Statin and dose No. of patients
Atorvastatin 197 Pravastatin 21
5 mg 4 10 mg 2
10 mg 103 20 mg 10
20 mg 62 40 mg 8
30 mg 1 80 mg 1
40 mg 20 Fluvastatin 8
60 mg 1 20 mg 2
80 mg 6 40 mg 6
Simvastatin 126 Lovastatin 7
10 mg 16 20 mg 6
20 mg 65 80 mg 1
40 mg 35 Rosuvastatin 4





in the generalized estimating equation models as covariates. We excluded
operative deaths without stroke or PMI from the models for stroke and
PMI, respectively. Statistical analysis was performed with SAS version
9.1 (SAS Institute Inc, Cary, NC).
RESULTS
Preoperative Characteristics
Patient characteristics are shown in Table 2. Patients in
the statin group were older and had higher body mass index,
higher smoking frequency, hypertension, diabetes, chronic
obstructive pulmonary disease, and cerebrovascular acci-
dent. They had more diagnoses of aortic valve disease and
fewer diagnoses of mitral valve disease. In addition, there
was a higher frequency of preoperative use of beta-blockers,
angiotensin-converting enzyme inhibitors, and aspirin, and
more procedures were performed in 2005.





(n ¼ 1026) P value
Age 66.6  11.8 59.6  15.5 <.001
Male 184 (50.7%) 573 (55.8%) .090
Body mass index 28.1  6.0 26.6  5.7 <.001
History of smoking 184 (50.7%) 431 (42.0%) .004
Current smoking 26 (7.2%) 95 (9.3%) .224
Family history
of CAD
76 (20.9%) 170 (16.6%) .061
Diabetes 56 (15.4%) 273 (35.8%) <.001
Renal insufficiency 21 (5.8%) 45 (4.4%) .282
Hemodialysis 3 (0.8%) 4 (0.4%) .313
Hypertension 226 (62.3%) 418 (40.7%) <.001
COPD 63 (6.9%) 114 (11.1%) .002
Peripheral vascular disease 53 (14.6%) 137 (13.4%) .552
History of CVA 25 (6.9%) 36 (3.5%) .007
Recent CVA 0 (0%) 1 (0.1%) .552
Active endocarditis 5 (1.4%) 31 (3.0%) .090
NYHA class 3 or 4 185 (17.8%) 297 (28.9%) .078
History of CHF 122 (33.6%) 334 (32.6%) .713
Previous cardiac surgery 40 (11.0%) 142 (13.8%) .171
Atrial fibrillation 22 (6.1%) 48 (4.7%) .301
Ejection fraction 57.1  11.9 57.3  11.0 .743
Aortic valve disease 231 (63.6%) 516 (50.3%) <.001
Mitral valve disease 154 (42.4%) 576 (56.1%) <.001
Tricuspid valve disease 38 (10.5%) 117 (11.4%) .466
Other cardiac disease 102 (28.1%) 303 (29.5%) .606
Non-elective surgery 72 (19.8%) 167 (16.3%) .123
Preoperative IABP 0 (0%) 2 (0.2%) .400
Immunosuppressive therapy 17 (4.7%) 46 (4.5%) .875
Aspirin 192 (52.9%) 250 (24.4%) <.001
Beta blockers 129 (35.5%) 182 (17.7%) <.001
ACE inhibitors 59 (16.3%) 107 (10.4%) .003
Performed in 2003 85 (23.4%) 253 (24.7%) .635
Performed in 2004 102 (28.1%) 247 (24.1%) .129
Performed in 2005 142 (39.1%) 283 (27.6%) <.001
ACE, Angiotensin-converting enzyme; CAD, coronary artery disease; CHF, conges-
tive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascu-
lar accident; IABP, intraaortic balloon pump; NYHA, New York Heart Association.Cardiovascular Surgery c Volume 136, Number 6 1511




The crude operative mortality was 0.8% (3/363) and
2.3% (24/1,026), the crude incidence of stroke was 1.7%
(6/360) and 2.9% (29/1007), and the crude incidence of
PMI was 2.2% (8/362) and 2.4% (24/1005) in the statin
and non-statin groups, respectively.
Generalized estimating equations showed that preopera-
tive statin use was associated with lower mortality (odds ra-
tio: 0.25, 95% confidential interval: 0.12–0.54, P ¼ .0004)
and not significantly associated with an incidence of stroke
(odds ratio: 0.48, 95% confidential interval: 0.19–1.22,
P¼ .1215) or PMI (odds ratio: 0.91, 95% confidential inter-
val: 0.43–1.91, P ¼ .8025) in this cohort.
Comment
The mortality and morbidity of patients undergoing car-
diac surgery is declining with improved surgical techniques,
technologies, and perioperative care. Previous studies indi-
cate that preoperative administration of statins could be
a strategy for improving CABG outcomes.10-12 However,
whether preoperative statins improve the operative out-
comes of patients undergoing cardiac surgery with no
history of CAD is unknown.
Clark and colleagues16 performed an 8-year retrospective
cohort study and reported beneficial effects of preoperative
statins on the mortality and morbidity in patients undergoing
various assortments of cardiac surgical procedures (80% of
patients underwent CABG). In the subgroup of patients un-
dergoing valve replacement or repair only, patients receiving
statins had a lower mortality than patients not receiving sta-
tins (1.96% vs 7.5%). However, this study’s subgroup anal-
ysis was not statistically powerful and the history of CAD
was not sufficiently clarified to be capable of demonstrating
a benefit in patients without CAD.
We have shown a significant association of preoperative
statin use with lower operative mortality in patients without
CAD who underwent cardiac valve surgery. Preoperative
statin use was not significantly associated with a lower inci-
dence of new stroke; however, the results of a multivariable
analysis (odds ratio, 0.48; 95% confidential interval, 0.19–
1.22) imply that further investigation with a larger sample
size or different study design would be worthwhile. There
was no association between preoperative statin use and the
incidence of PMI in this cohort.
The pleiotropic effects of statins may be an important
biological mechanism underlying the beneficial effect of pre-
operative statins, although this is not causally proven and
would warrant further investigation. The pleiotropic effects
include improving endothelial function, enhancing the stabil-
ity of atherosclerotic plaques, decreasing oxidative stress and
inflammation, and inhibiting the thrombogenic response.1
These effects may attenuate the proinflammatory effects of
surgical invasiveness and CPB. The exposure to CPB causes1512 The Journal of Thoracic and Cardiovascular Sa systemic inflammatory reaction culminating in organ injury
and impaired function. Strategies to minimize CPB-related
systemic inflammatory reactions include improvement of
artificial surface biocompatibility, temporary inhibition of
blood cell activation, and blockage of the bioactivities and ef-
fects of inflammatory mediators.17 Statins are known to sup-
press inflammatory mediators. Recent studies have shown
that preoperative statin use suppresses serum levels of in-
flammatory markers after CABG.18-20
Stroke is a major complication after cardiac surgery.
Mechanisms of perioperative stroke include cerebral hypo-
perfusion and thromboembolism. Statins have been shown
to reduce brain injury in animal models of cerebral ischemia
by up-regulating endothelial nitric oxide synthase.21 A pre-
vious study showed that preoperative statin use improves en-
dothelial function after CABG.22 Anti-inflammatory and
antioxidant effects of statins can also be neuroprotective in
cerebral ischemia.21 In addition, there is strong evidence
that statins accelerate the breakdown of proinflammatory
extracellular nucleotides and promote the formation of
anti-inflammatory adenosine, a well-known and potent neu-
roprotectant.23 Clinically, preoperative statins have been
shown to reduce perioperative stroke in patients undergoing
CABG.24 Although a neuroprotective effect of statins in
non-CABG cardiac surgery has not been reported, it seems
biologically reasonable.
The majority of the patients in our cohort who were taking
statins preoperatively were doing so because of their history
of hypercholesterolemia. Decreasing serum cholesterol
levels because of preoperative use of statins could be a reason
for the beneficial effect that was observed. We did not
include preoperative serum cholesterol levels in the analysis
because they were not measured in all patients.
Clinically, this study implies that a preemptive use of
preoperative statins may improve operative outcomes in
patients undergoing cardiac valve surgery who do not
have a history of CAD. Our cohort includes concomitant
aortic, congenital, and other cardiac procedures. Combined
with previous findings in CABG and patients with CAD,
the beneficial effects of preoperative statins may be general-
izable to most patients undergoing cardiac surgery.
A limitation of this study is its observational nature. How-
ever, we minimized confounding effects by using the multi-
variable and propensity analyses. There are potential
confounders we did not include in the propensity score
(eg, pulmonary artery pressure, cardiac index, and use of
aprotinin). Furthermore, this is a retrospective, single-center
study. The clinical impact of these results may warrant a fu-
ture prospective multicenter randomized controlled trial.
Our study did not identify the optimal dose of preoperative
statins because our patients were receiving various classes
and doses of statins. Previous randomized controlled studies
have shown that the administration of atorvastatin 20 mg/
d for 3 weeks before surgery has beneficial effects in patientsurgery c December 2008
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study has shown that administration of atorvastatin 40 mg/
d for 7 days before surgery reduced the incidence of postop-
erative atrial fibrillation.25 Other studies have shown that 1
to 5 days of use of statins may improve endothelial func-
tion,26 reduce inflammation,27 and improve outcome.
Further investigations are necessary to determine the optimal
dose of preoperative statins.
CONCLUSIONS
Preoperative use of statins is associated with lower oper-
ative mortality in patients without CAD who underwent
cardiac valve surgery. Preoperative statins may be useful
for improving operative outcomes in patients without
CAD who undergo cardiac surgery.
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